阿斯利康完成$41亿收购百时美施贵宝全球糖尿病联盟股份

作者：tomato来源：生物谷

关键词： 阿斯利康 百时美施贵宝 糖尿病联盟

                               
登录/注册后可看大图

2014年2月12日讯 /生物谷BIOON/ --阿斯利康（AstraZeneca）2月3日宣布，已成功完成对商业合作伙伴百时美施贵宝（BMS）在全球糖尿病联盟中全部股份的收购。阿斯利康已支付21亿美元，并已同意支付14亿美元的监管、上市和销售付款，以及各种销售相关的特许权使用费，其中6亿美元为Farxiga在美国获批的监管里程碑及相关费用。此外，在特定资产随后转交后，阿斯利康可能还会支付2.25亿美元。

正如先前所公布的，此次收购将使阿斯利康获得双方联盟中糖尿病业务知识产权及开发、生产、商业化全球权利的所有权，该业务包括：Onglyza（saxagliptin，沙格列汀）、Kombiglyze（沙格列汀+盐酸二甲双胍缓释）、Komboglyze（沙格列汀+盐酸二甲双胍）、dapagliflozin（达帕格列净，美国以外地区商品名为Forxiga，美国商品名Farxiga）、Xigduo（dapagliflozin+二甲双胍）、Byetta（exenatide，艾塞那肽）、Bydureon（艾塞那肽缓释注射悬液）、metreleptin（美曲普汀）、Symlin（普兰林肽乙酸酯）。

据了解，阿斯利康和百时美施贵宝在2007年1月达成了全球糖尿病联盟，目的是联合开发用以治疗2型糖尿病的药物。此后，两家的合作又有所拓展，2012年8月，双方共同斥资53亿美元收购Amylin制药公司。随后这种合作关系进一步拓宽，将其他一些与糖尿病相关的产品覆盖在内。

此前，不少业内人士指出，阿斯利康此番大手笔投入糖尿病制药业务，是其在新药开发乏力背景下的一次“豪赌”，公司未来几年将面临很大的业绩压力。（生物谷Bioon.com）

英文原文：AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance

Monday, 3 February 2014

AstraZeneca today announced that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance.

As previously announced, the acquisition gives AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, which includes Onglyza® (saxagliptin), Kombiglyze™ XR (saxagliptin and metformin HCl extended release), Komboglyze™ (saxagliptin and metformin HCl), dapagliflozin (marketed as Forxiga® outside the US and Farxiga® in the US), Xigduo™ (dapagliflozin and metformin HCl), Byetta® (exenatide), Bydureon® (exenatide extended-release for injectable suspension), metreleptin and Symlin® (pramlintide acetate).

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “I extend a warm welcome to our new colleagues and I’m delighted with the speed at which we’ve completed the acquisition which reinforces our long-term commitment to patients with diabetes. Under a single leadership, we will maximise the potential of our innovative portfolio of non-insulin anti-diabetic medicines, bringing fresh momentum to our growth ambitions for this franchise.”

On completion of the acquisition, AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.

NOTES TO EDITORS

About Type 2 Diabetes

In 2013, diabetes was estimated to affect more than 380 million people worldwide. The prevalence of diabetes is projected to reach more than 592 million by 2035. Type 2 diabetes accounts for approximately 85% to 95% of all cases of diagnosed diabetes in adults.

Type 2 diabetes is a chronic disease characterised by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycaemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

(责任编辑：lishuheng)